Skip to main content

Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

The Original Article was published on 24 December 2021

Correction to: Malaria Journal (2021) 20:484 https://doi.org/10.1186/s12936-021-04021-5

Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article.

Where it should read:

  • Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https://pactr.samrc.ac.za/) with study Trial No. PACTR201811640750761.

It said:

  • Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761.

The original article has been updated accordingly.

Reference

  1. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, Asua V, Gudoi S, Kigozi R, Tibenderana J, Bwanika JB, Bosco A, Rubahika D, Kyabayinze D, Opigo J, Rutazana D, Sebikaari G, Belay K, Niang M, Halsey ES, Moriarty LF, Lucchi NW, Svigel Souza SS, Nsobya SL, Kamya MR, Yeka A. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484. https://doi.org/10.1186/s12936-021-04021-5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chris Ebong.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ebong, C., Sserwanga, A., Namuganga, J.F. et al. Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J 21, 37 (2022). https://doi.org/10.1186/s12936-022-04049-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12936-022-04049-1